ArticleClinical, cosmetic and investigational dermatology2025
Prox1 Is Linked to Metastasis and Poor Prognosis by Promoting Lymphangiogenesis in Melanoma.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultra-High-Frequency Ultrasound of Melanoma Excision Scars for Detection of Clinically Occult Local Recurrence: A Single-Center Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study is to investigate the role of Prox1 in the progression of cutaneous melanoma (CMM) and its relationship with lymphatic metastasis. Methods and Results: By analyzing the data from the Cancer Genome Atlas (TCGA), we found that the expression of Prox1 and LYVE1 was significantly upregulated in the metastatic melanoma group. Additionally, elevated levels of Prox1 were associated with shorter survival times. Correlation analysis demonstrated a significant relationship between Prox1 and markers associated with lymphangiogenesis, including LYVE1, FLT4, FOXC2, and ANGPT2. A clinical study involving 32 cases of CMM was conducted to analyze Prox1 expression and its relationship with lymphangiogenesis and clinicopathological characteristics. Research revealed that Prox1 was expressed significantly higher in patients with lymph node (LN) metastasis and in those classified as stage 3C-4. Additionally, the density of lymphatic vessels(LVD) in the LN metastasis group and the stage 3C-4 group was markedly higher than in the group without lymph node metastasis and in the stage 0-3B group. Furthermore, Breslow thickness was found to correlate with both Prox1 expression and LVD. Prox1-positive expression was associated with increased LVD. Further investigation was conducted on the role of Prox1 in the CMM cell line A375 and its derived exosomes. Exosomes were collected from CMM Conclusion: Prox1 played an important role in promoting cell proliferation, migration, and lymphangiogenesis, which is related to tumor metastasis and poor prognosis. These results indicated the potential importance of Prox1 as a biomarker, which is expected to lead to the development of a new insight for anti-tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.